

## LOREDANA Concetta CIFALDI

### Personal information

Address: Via Pomezia, 44/A/6 00183 Rome-Italy

Telephone(s): 0039 3382396587

E-mails: cifaldi@med.uniroma2.it

loredana\_cifaldi@yahoo.it

Nationality: Italian

Date of birth: June 4<sup>th</sup> 1974



### Education and professional experience

- July 1997: Graduated in Biological Science, vote 110/110, University of Camerino
- September 1998: Licence for Biologist profession
- Jan 1998-Jul 2001: Specialist in Clinical Biochemistry, School of Clinical Biochemistry, University of Torino Laboratory of Immunology of Prof. Guido Forni; University of Camerino Laboratory of Prof. Evandro Fioretti.
- Sept 2001-Aug 2003: University Research Contract at "La Sapienza" University in Rome, Laboratory of Immunology of Prof. Angela Santoni.
- Sept 2003-Nov 2004: Fondazione Pasteur-Cenci Bolognetti fellowship at "La Sapienza" University in Rome, Laboratory of Immunology of Prof. Angela Santoni.
- Dec 2004-Nov 2005: Fondation de la Recherche Medical (FRM) fellowship at Pasteur Institute in Paris, France, Unité Cytokines et Développement Lymphoide Laboratory of Immunology of Dr James Di Santo.
- Febr-Dec 2006: Research fellow at Istituto Dermopatico dell'Immacolata IRCCS in Rome, Italy, Laboratory of Immunology and Allergology of Dr Andrea Cavani.
- Jan 2007-Jul 2023: Research contract at Bambino Gesù Children's Hospital, Rome, Italy, Department of Paediatric Haematology/Oncology of Prof. Franco Locatelli; Academic Department of Pediatrics (DPUO) of Prof. Paolo Rossi.
- Jul 2020-Jul 2023: Assistant professor (tenure track) RTDb, Department of Clinical Sciences and Translational Medicine, Faculty of Medicine, University of Rome "Tor Vergata", Laboratory of Prof. Roberto Bei.
- Jul 2023: Associate Professor of General Pathology (SSD MED/04), Department of Clinical Sciences and Translational Medicine, Faculty of Medicine, University of Rome "Tor Vergata".

Registration in the Register of Biologists, Special List: Cod EA\_020119.

### Main activities and responsibilities:

The majority of projects of Dr Cifaldi aims to develop new NK cell-based Immunotherapies. Dr Cifaldi has a strong knowledge and experimental background in tumor immunology and in particular in NK cell activities in mice and human. Her studies have been recognized at the international level with publications in peer reviewed journals.

## **Awards/Honors**

### **Research Grants:**

#### **Ministero della Salute**

- Principal Investigator (PI) – Young Researcher (under 40years), Project code: GR-2011-02352151
- Collaborator (PI Dr Giusi Prencipe) – Young Researcher (under 40years), Project code: GR-2011-02347874
- PI - Ricerca Corrente 5 X 1000 grant 2020

#### **Ministero dell'Università e della Ricerca**

- Collaborator: PRIN 2020, settore ERC: LS3, 20205HZBP8 (PI Michele Milella)
- CoPI: PRIN 2022, settore ERC: LS6, 20223RRASS, (PI Marco Cippitelli)
- CoPI: PRIN 2022 PNRR, settore ERC: LS3, 2022XZKBM, (PI Raffaele Strippoli)
- PI: FISA 2022, settore Biotechnology: FISA-2022-00497

## **National Scientific Qualifications (Abilitazione Scientifica Nazionale) for Associate**

Professor (fascia II) in:

- Patologia Generale e Patologia Clinica -06/A2
- Scienze delle Professioni Sanitarie e delle Tecnologie Mediche Applicate-06/N1

## **Teaching activities**

Lecturer in General Pathology for the courses in:

- Medicina e Chirurgia
- Medicine and Surgery (in english)
- Biotecnologie Mediche
- Scienze Motorie
- Scienze e Tecniche dello Sport

Faculty of Medicine, University of Rome "Tor Vergata", Rome, Italy.

Lecturer in Immunology for Medicina e Chirurgia, Faculty of Medicine, University of Nostra Signora del Buon Consiglio, Tirana, Albania.

## **PhD and degree supervision**

Tutor for PhD students:

- PhD program in Scienze Immunologiche Ematologiche e Reumatologiche, 2015-2017, University of Rome "La Sapienza", Rome, Italy.
- PhD program in Immunologia e Biotecnologie Applicate, 2016-2018, University of Rome "Tor Vergata", Rome, Italy.
- PhD program in Immunologia, Medicina Molecolare e Biotecnologie Applicate, 2023-2026, University of Rome "Tor Vergata", Rome, Italy.
- PhD program in Tissue Engineering and Remodeling Biotechnologies for Body Function, 2023-2026, University of Rome "Tor Vergata", Rome, Italy.
- Tutor of Degree in Biotechnology (Tor Vergata University)

- Tutor of Degree in Scienze e Tecniche dello Sport (Tor Vergata University)

## Editorial activities

- Ad-hoc reviewer: OncoImmunology, AutoImmunity, PlosOne, Gene, Journal of Stem Cell Research & Therapeutics, ACAMC, British journal of Cancer, Innate Immunity, OncoTarget and Therapy, Scientific Reports, Frontiers in Immunology, Cancers, JACI
- Editorial contributions: Frontiers in Immunology, editor for a Research Topic titled: Molecular strategies aimed to boost NK cell-based Immunotherapy of cancer; International Journal of Molecular Sciences, guest editor for a Special Issue titled: The Effect of Dietary Factors on Cancer 3.0

## Membership of scientific society

Member of the Società Italiana di Immunologia, Immunologia Clinica ed Allergologia (S.I.I.C.A.).

## Publications (\*corresponding author)

1. Curcumin potentiates the ErbB receptors inhibitor Afatinib for enhanced antitumor activity in malignant mesothelioma  
Benvenuto M, Nardozi D, Palumbo C, Focaccetti C, Carrano R, Angiolini V, **Cifaldi L**, Lucarini V, Mancini P, Kärpi B, Currenti W, Bei R, Masuelli L. Int J Food Sci Nutr. 2023 Sep 3:1-14. doi: 10.1080/09637486.2023.2251723.
2. DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy.  
**Cifaldi L\***, Melaiu O, Giovannoni R, Benvenuto M, Focaccetti C, Nardozi D, Barillari G, Bei R. Front Immunol. 2023 Jun 8;14:1197053.doi: 10.3389/fimmu.2023.1197053.
3. Different outcome of targeting ERN1/IRE1 alpha and EIF2AK3/PERK in NSG mice engrafted with primary effusion lymphoma.  
Arena A, Romeo MA, Focaccetti C, Anastasiadou E, Trivedi P, **Cifaldi L**, Gilardini Montani MS, Benedetti R, Santarelli R, Gonnella R, Benvenuto M, Marchese C, Masuelli L, Bei R, Cirone M. Br J Haematol. 2023 Feb 12. doi: 10.1111/bjh.18688. PMID: 36775956
4. Recent finding on the impact of ErbB receptor status on prognosis and therapy of head and neck squamous cell carcinoma.  
Palumbo C, Benvenuto M, Focaccetti C, Albonici L, **Cifaldi L**, Rufini A, Nardozi D, Angiolini V, Bei A, Masuelli L, and Bei R. Frontiers in Medicine. 2023 Feb 2;10:1066021. Doi:10.3389/fmed.2023.1066021. PMID: 36817764.
5. DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells *in vitro*: a proof-of-concept study.  
Focaccetti C, Benvenuto M, Pighi C, Vitelli A, Napolitano F, Cotugno N, Fruci D, Palma P, Rossi P, Bei R, **Cifaldi L\***. Front Immunol. 2022 Jul 28;13:886319. doi: 10.3389/fimmu.2022.886319. eCollection 2022.PMID: 35967339
6. Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy.  
D'Amico S, Tempora P, Melaiu O, Lucarini V, **Cifaldi L**, Locatelli F, Fruci D. Front Immunol. 2022 Jul 22;13:948297. doi: 10.3389/fimmu.2022.948297. eCollection 2022.PMID: 35936007
7. Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both *in vitro* and *in vivo*.  
Bei R, Benvenuto M, Focaccetti C, Fazi S, Moretti M, Nardozi D, Angiolini V, Ciuffa S, **Cifaldi L**, Carrano R, Palumbo C, Miele MT, Bei R, Barillari G, Manzari V, De Smaele E, Modesti A, Masuelli L. J Transl Med. 2022 Jun 25;20(1):286. doi: 10.1186/s12967-022-03490-9.PMID: 35752861
8. ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function.

- D'Amico S, D'Alicandro V, Compagnone M, Tempora P, Guida G, Romania P, Lucarini V, Melaiu O, Falco M, Algeri M, Pende D, **Cifaldi L**, Fruci D. Front Immunol. 2021 Nov 30;12:778103. doi: 10.3389/fimmu.2021.778103. eCollection 2021.PMID: 34917091
9. Polyphenols affect the humoral response in cancer, infectious and allergic diseases and autoimmunity by modulating the activity of T<sub>H1</sub> and T<sub>H2</sub> cells.  
Benvenuto M, Focaccetti C, Ciuffa S, Fazi S, Bei A, Miele MT, Albonici L, **Cifaldi L**, Masuelli L, Bei R. Curr Opin Pharmacol. 2021 Oct;60:315-330. doi: 10.1016/j.coph.2021.08.005. Epub 2021 Sep 11.PMID: 34520942
10. Enhancement of Neuroblastoma NK-Cell-Mediated Lysis through NF-κB p65 Subunit-Induced Expression of FAS and PVR, the Loss of Which Is Associated with Poor Patient Outcome.  
Brandetti E, Focaccetti C, Pezzolo A, Ognibene M, Folgiero V, Cotugno N, Benvenuto M, Palma P, Manzari V, Rossi P, Fruci D, Bei R, **Cifaldi L\***. Cancers (Basel). 2021 Aug 29;13(17):4368. doi: 10.3390/cancers13174368.PMID: 34503178
11. Virological and immunological features of SARS-COV-2 infected children with distinct symptomatology.  
Cotugno N, Ruggiero A, Pascucci GR, Bonfante F, Petrara MR, Pighi C, **Cifaldi L**, Zangari P, Bernardi S, Corsi L, Santilli V, Manno EC, Amodio D, Linardos G, Piccioni L, Barbieri MA, Perrotta D, Campana A, Donà D, Giaquinto C; CACTUS Study Team; Concato C, Brodin P, Rossi P, De Rossi A, Palma P. Pediatr Allergy Immunol. 2021 Nov;32(8):1833-1842. doi: 10.1111/pai.13585. Epub 2021 Jul 16.PMID: 34174102
12. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFN $\gamma$  overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.  
Caforio M, Sorino C, Caruana I, Weber G, Camera A, **Cifaldi L**, De Angelis B, Del Bufalo F, Vitale A, Goffredo BM, De Vito R, Fruci D, Quintarelli C, Fanciulli M, Locatelli F, Folgiero V. J Immunother Cancer. 2021 Mar;9(3):e001502. doi: 10.1136/jitc-2020-001502.PMID: 33737337
13. The immune system view of the coronavirus SARS-CoV-2.  
Celardo I, Pace L, **Cifaldi L**, Gaudio C, Barnaba V. Biol Direct. 2020 Dec 29;15(1):30. doi: 10.1186/s13062-020-00283-2.PMID: 33371901
14. Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors.  
Veneziani I, Infante P, Ferretti E, Melaiu O, Battistelli C, Lucarini V, Compagnone M, Nicoletti C, Castellano A, Petrini S, Ognibene M, Pezzolo A, Di Marcotullio L, Bei R, Moretta L, Pistoia V, Fruci D, Barnaba V, Locatelli F, **Cifaldi L\***. Cancer Immunol Res. 2021 Feb;9(2):170-183. doi: 10.1158/2326-6066.CIR-20-0313. Epub 2020 Dec 10.PMID: 33303573
15. Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma.  
Melaiu O, Chierici M, Lucarini V, Jurman G, Conti LA, De Vito R, Boldrini R, **Cifaldi L**, Castellano A, Furlanello C, Barnaba V, Locatelli F, Fruci D. Nat Commun. 2020 Nov 25;11(1):5992. doi: 10.1038/s41467-020-19781-y.PMID: 33239635
16. PlGF Immunological Impact during Pregnancy.  
Albonici L, Benvenuto M, Focaccetti C, **Cifaldi L**, Miele MT, Limana F, Manzari V, Bei R. Int J Mol Sci. 2020 Nov 18;21(22):8714. doi: 10.3390/ijms21228714.PMID: 33218096
17. IFNAR2 Deficiency Causing Dysregulation of NK Cell Functions and Presenting With Hemophagocytic Lymphohistiocytosis.  
Passarelli C, Civino A, Rossi MN, **Cifaldi L**, Lanari V, Moneta GM, Caiello I, Bracaglia C, Montinaro R, Novelli A, De Benedetti F, Prencipe G. Front Genet. 2020 Sep 18;11:937. doi: 10.3389/fgene.2020.00937. eCollection 2020.PMID: 33193576
18. Polyphenol-Mediated Autophagy in Cancer: Evidence of In Vitro and In Vivo Studies.  
Benvenuto M, Albonici L, Focaccetti C, Ciuffa S, Fazi S, **Cifaldi L**, Miele MT, De Maio F, Tresoldi I, Manzari V, Modesti A, Masuelli L, Bei R. Int J Mol Sci. 2020 Sep 10;21(18):6635. doi: 10.3390/ijms21186635.PMID: 32927836
19. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.  
**Cifaldi L\***, Di Santo J, Olive D. Front Immunol. 2020 Jun 16;11:1132. doi: 10.3389/fimmu.2020.01132. eCollection 2020.PMID: 32612604
20. Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.

- Melaiu O, Lucarini V, **Cifaldi L\***, Fruci D. Front Immunol. 2020 Jan 21;10:3038. doi: 10.3389/fimmu.2019.03038. eCollection 2019.PMID: 32038612
21. DNAM-1 Activating Receptor and Its Ligands: How Do Viruses Affect the NK Cell-Mediated Immune Surveillance during the Various Phases of Infection?  
**Cifaldi L\***, Doria M, Cotugno N, Zicari S, Cancrini C, Palma P, Rossi P. Int J Mol Sci. 2019 Jul 30;20(15):3715. doi: 10.3390/ijms20153715.PMID: 31366013
22. The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors.  
Veneziani I, Fruci D, Compagnone M, Pistoia V, Rossi P, **Cifaldi L\***. Oncotarget. 2019 Mar 15;10(22):2151-2160. doi: 10.18632/oncotarget.26736. eCollection 2019 Mar 15.PMID: 31040907
23. Regulation of ERAP1 and ERAP2 genes and their dysfunction in human cancer.  
Compagnone M, **Cifaldi L**, Fruci D. Hum Immunol. 2019 May;80(5):318-324. doi: 10.1016/j.humimm.2019.02.014. Epub 2019 Feb 27.PMID: 30825518
24. Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors.  
Boldrini R, De Pasquale MD, Melaiu O, Chierici M, Jurman G, Benedetti MC, Salfi NC, Castellano A, Collini P, Furlanello C, Pistoia V, **Cifaldi L**, Terenziani M, Fruci D. Oncoimmunology. 2018 Dec 13;8(2):e1542245. doi: 10.1080/2162402X.2018.1542245. eCollection 2019.PMID: 30713803
25. Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.  
Veneziani I, Brandetti E, Ognibene M, Pezzolo A, Pistoia V, **Cifaldi L\***. J Immunol Res. 2018 Apr 1;2018:4972410. doi: 10.1155/2018/4972410. eCollection 2018.PMID: 29805983
26. Identification of GAD65 AA 114-122 reactive 'memory-like' NK cells in newly diagnosed Type 1 diabetic patients by HLA-class I pentamers.  
Perri V, Gianhecchi E, **Cifaldi L**, Pellegrino M, Giorda E, Andreani M, Cappa M, Fierabracci A. PLoS One. 2017 Dec 13;12(12):e0189615. doi: 10.1371/journal.pone.0189615. eCollection 2017.PMID: 29236750
27. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.  
**Cifaldi L\***, Locatelli F, Marasco E, Moretta L, Pistoia V. Trends Mol Med. 2017 Dec;23(12):1156-1175. doi: 10.1016/j.molmed.2017.10.002. Epub 2017 Nov 10.PMID: 29133133
28. Identification of a Genetic Variation in ERAP1 Aminopeptidase that Prevents Human Cytomegalovirus miR-UL112-5p-Mediated Immuno-evasion.  
Romania P, **Cifaldi L**, Pignoloni B, Starc N, D'Alicandro V, Melaiu O, Li Pira G, Giorda E, Carrozzo R, Bergvall M, Bergström T, Alfredsson L, Olsson T, Kockum I, Seppälä I, Lehtimäki T, Hurme MA, Hengel H, Santoni A, Cerboni C, Locatelli F, D'Amato M, Fruci D. Cell Rep. 2017 Jul 25;20(4):846-853. doi: 10.1016/j.celrep.2017.06.084.PMID: 28746870
29. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.  
Brandetti E, Veneziani I, Melaiu O, Pezzolo A, Castellano A, Boldrini R, Ferretti E, Fruci D, Moretta L, Pistoia V, Locatelli F, **Cifaldi L\***. Oncoimmunology. 2017 Apr 20;6(6):e1316439. doi: 10.1080/2162402X.2017.1316439. eCollection 2017.PMID: 28680748
30. NK cell effector functions in a Chédiak-Higashi patient undergoing cord blood transplantation: Effects of in vitro treatment with IL-2.  
**Cifaldi L\***, Pinto RM, Rana I, Caniglia M, Angioni A, Petrocchi S, Cancrini C, Cursi L, Palumbo G, Zingoni A, Gismondi A, Rossi P, Santoni A, Cerboni C. Immunol Lett. 2016 Dec;180:46-53. doi: 10.1016/j.imlet.2016.10.009. Epub 2016 Nov 2.PMID: 27816481
31. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome.  
**Cifaldi L**, Prencipe G, Caiello I, Bracaglia C, Locatelli F, De Benedetti F, Strippoli R. Arthritis Rheumatol. 2015 Nov;67(11):3037-46. doi: 10.1002/art.39295.PMID: 26251193
32. TIM-3/Gal-9 interaction induces IFN $\gamma$ -dependent IDO1 expression in acute myeloid leukemia blast cells.  
Folgiro V, **Cifaldi L**, Li Pira G, Goffredo BM, Vinti L, Locatelli F. J Hematol Oncol. 2015 Apr 16;8:36. doi: 10.1186/s13045-015-0134-4.PMID: 25886742

33. ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors.  
**Cifaldi L**, Romania P, Falco M, Lorenzi S, Meazza R, Petrini S, Andreani M, Pende D, Locatelli F, Fruci D. Cancer Res. 2015 Mar 1;75(5):824-34. doi: 10.1158/0008-5472.CAN-14-1643. Epub 2015 Jan 15.PMID: 25592150
34. T and NK cells: two sides of tumor immunoevasion.  
Fruci D, Lo Monaco E, **Cifaldi L**, Locatelli F, Tremante E, Benevolo M, Giacomini P. J Transl Med. 2013 Feb 4;11:30. doi: 10.1186/1479-5876-11-30.PMID: 23379575
35. IRF1 and NF- $\kappa$ B restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma.  
Lorenzi S, Forloni M, **Cifaldi L**, Antonucci C, Citti A, Boldrini R, Pezzullo M, Castellano A, Russo V, van der Bruggen P, Giacomini P, Locatelli F, Fruci D. PLoS One. 2012;7(10):e46928. doi: 10.1371/journal.pone.0046928. Epub 2012 Oct 5.PMID: 23071666
36. Role of endoplasmic reticulum aminopeptidases in health and disease: from infection to cancer.  
**Cifaldi L**, Romania P, Lorenzi S, Locatelli F, Fruci D. Int J Mol Sci. 2012;13(7):8338-8352. doi: 10.3390/ijms13078338. Epub 2012 Jul 4.PMID: 22942706
37. ERAAP modulation: A possible novel strategy for cancer immunotherapy?  
Fruci D, Locatelli F, **Cifaldi L**. Oncoimmunology. 2012 Jan 1;1(1):81-82. doi: 10.4161/onci.1.1.17828.PMID: 22720218
38. ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis.  
Galeano F, Rossetti C, Tomaselli S, **Cifaldi L**, Lezzerini M, Pezzullo M, Boldrini R, Massimi L, Di Rocco CM, Locatelli F, Gallo A. Oncogene. 2013 Feb 21;32(8):998-1009. doi: 10.1038/onc.2012.125. Epub 2012 Apr 23.PMID: 22525274
39. Hedgehog/hyaluronic acid interaction network in nonalcoholic fatty liver disease, fibrosis, and hepatocellular carcinoma.  
Pazzaglia S, **Cifaldi L**, Saran A, Nobili V, Fruci D, Alisi A. Hepatology. 2012 Oct;56(4):1589. doi: 10.1002/hep.25783.PMID: 22505342
40. Major histocompatibility complex class I and tumour immuno-evasion: how to fool T cells and natural killer cells at one time.  
Fruci D, Benevolo M, **Cifaldi L**, Lorenzi S, Lo Monaco E, Tremante E, Giacomini P. Curr Oncol. 2012 Feb;19(1):39-41. doi: 10.3747/co.19.945.PMID: 22328841
41. Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing.  
**Cifaldi L**, Lo Monaco E, Forloni M, Giorda E, Lorenzi S, Petrini S, Tremante E, Pende D, Locatelli F, Giacomini P, Fruci D. Cancer Res. 2011 Mar 1;71(5):1597-606. doi: 10.1158/0008-5472.CAN-10-3326. Epub 2011 Jan 20.PMID: 21252114
42. NF- $\kappa$ B, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells.  
Forloni M, Albini S, Limongi MZ, **Cifaldi L**, Boldrini R, Nicotra MR, Giannini G, Natali PG, Giacomini P, Fruci D. Cancer Res. 2010 Feb 1;70(3):916-24. doi: 10.1158/0008-5472.CAN-09-2582. Epub 2010 Jan 26.PMID: 20103633
43. HLA-E and the origin of immunogenic self HLA epitopes.  
Lo Monaco E, Tremante E, **Cifaldi L**, Fruci D, Giacomini P. Mol Immunol. 2010 May;47(9):1661-2; author reply 1163-4. doi: 10.1016/j.molimm.2009.12.018. Epub 2010 Jan 22.PMID: 20096934
44. CD56<sup>high</sup>CD16-CD62L<sup>-</sup> NK cells accumulate in allergic contact dermatitis and contribute to the expression of allergic responses.  
Carbone T, Nasorri F, Pennino D, Eyerich K, Foerster S, **Cifaldi L**, Traidl-Hoffman C, Behrendt H, Cavani A. J Immunol. 2010 Jan 15;184(2):1102-10. doi: 10.4049/jimmunol.0902518. Epub 2009 Dec 11.PMID: 20008290
45. Chronic eczema in a patient with Leukocyte Adhesion Deficiency (LAD) type I.  
Eyerich K, **Cifaldi L**, Notarangelo LD, Porta F, Notarangelo L, Mazzolari E, Fiorini M, Paradisi A, Cavani A. Eur J Dermatol. 2009 Jan-Feb;19(1):78-9. doi: 10.1684/ejd.2008.0552.PMID: 19171538
46. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM.  
Fontana L, Fiori ME, Albini S, **Cifaldi L**, Giovinazzi S, Forloni M, Boldrini R, Donfrancesco A, Federici V, Giacomini P, Peschle C, Fruci D. PLoS One. 2008 May 21;3(5):e2236. doi: 10.1371/journal.pone.0002236.PMID: 18493594
47. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect.

Gismondi A, **Cifaldi L**, Mazza C, Giliani S, Parolini S, Morrone S, Jacobelli J, Bandiera E, Notarangelo L, Santoni A. Blood. 2004 Jul 15;104(2):436-43. doi: 10.1182/blood-2003-07-2621. Epub 2004 Mar 4.PMID: 15001467

48. Proline-rich tyrosine kinase 2 and Rac activation by chemokine and integrin receptors controls NK cell transendothelial migration.

Gismondi A, Jacobelli J, Strippoli R, Mainiero F, Soriani A, **Cifaldi L**, Piccoli M, Frati L, Santoni A. J Immunol. 2003 Mar 15;170(6):3065-73. doi: 10.4049/jimmunol.170.6.3065.PMID: 12626562

49. Interleukin 12-activated lymphocytes influence tumor genetic programs.

Cavallo F, Quaglino E, **Cifaldi L**, Di Carlo E, André A, Bernabei P, Musiani P, Forni G, Calogero RA. Cancer Res. 2001 Apr 15;61(8):3518-23.PMID: 11309316

50. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia.

**Cifaldi L**, Quaglino E, Di Carlo E, Musiani P, Spadaro M, Lollini PL, Wolf S, Boggio K, Forni G, Cavallo F. Cancer Res. 2001 Apr 1;61(7):2809-12.PMID: 11306448

Main Bibliometric Indicators:

H index: 23 (Scopus)

Citations: 2075 (Scopus)

Roma li, 10 Gennaio 2024

Loredana Concetta Cifaldi

